Trial
NCT01806064
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tracon Pharmaceuticals Inc.
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
TRC105 and Axitinib
Why stopped
The study did not meet endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-19